Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 in Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis
NCT00457964Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Aug 2005
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Proportion of patients with angiomyolipoma volume decrease by 30% or more from baseline at 12 months. Started Aug 2005; status: completed.
02
Drugs
everolimus
03
Conditions
tuberous sclerosis complex (TSC)lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT00457964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457964.